Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599677 | 0.75 | MAPK14 (0.54) | MAPK14EGFRKDR | |
| SCHEMBL599476 | 0.74 | MAPK14 (0.56) | MAPK14EGFRKDR | |
| SCHEMBL599348 | 0.74 | MAPK14 (0.57) | MAPK14EGFRKDR | |
| SCHEMBL599340 | 0.72 | EGFR (0.49) | MAPK14EGFRKDR | |
| SCHEMBL600299 | 0.72 | KDR (0.49) | MAPK14EGFRKDR | |
| SCHEMBL600366 | 0.71 | KDR (0.47) | MAPK14EGFRKDR | |
| SCHEMBL600332 | 0.71 | SCN9A (0.44) | MAPK14EGFRKDRPTK2 | |
| SCHEMBL5946627 | 0.71 | BUB1 (0.43) | CCNE2CCNE1CDK2PTK2HTR2C | |
| SCHEMBL599999 | 0.70 | MAPK14 (0.49) | MAPK14ABL1EGFRKDR | |
| SCHEMBL599489 | 0.68 | MAPK14 (0.74) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | MAPK1, MAPK4, MAPK12 | GRM4 925/4885MAPK14 26/4885ABL1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.